Trade bodies representing the global life sciences industry have come together to urge coordinated steps to improve access to coronavirus vaccines.
In a statement, the groups said: “Immediate action must focus on stepping up responsible dose sharing and maximizing production without compromising quality or safety.”
The call to action has been issued by leading European trade group The European Federation of Pharmaceutical Industries and Associations (EFPIA) and the USA’s Pharmaceutical Research and Manufacturers of America (PhRMA), as well as several other national and regional bodies.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze